#ATS2018 – Potential CF Therapy ARO-ENaC Shows Promise in Studies

#ATS2018 – Potential CF Therapy ARO-ENaC Shows Promise in Studies

Arrowhead Pharmaceuticals’ investigational cystic fibrosis treatment candidate ARO-ENaC can effectively target the epithelial sodium channel alpha subunit (αENaC) in the lungs of rats, preclinical studies show. Given that ENaC is a well-known mediator of common cystic fibrosis symptoms, such as airway dehydration and mucus accumulation, these results suggest that ARO-ENaC may be a potential therapeutic […] The post #ATS2018 — Arrowhead’s Investigational CF Treatment ARO-ENaC Shows Potential in Preclinical Studies appeared first on Cystic Fibrosis News Today.

Read More